Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Roche-Phase-III-IMpower150-Study-Showed-TECENTRIQ-Atezolizumab-and-Avastin-Bevacizumab-Plus-Ch-25628300/?utm_source=whatsapp&utm_medium=social&utm_campaign=share